X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs AJANTA PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA AJANTA PHARMA ABBOTT INDIA/
AJANTA PHARMA
 
P/E (TTM) x 44.1 24.6 179.5% View Chart
P/BV x 11.0 10.1 108.7% View Chart
Dividend Yield % 0.6 0.6 102.9%  

Financials

 ABBOTT INDIA   AJANTA PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
AJANTA PHARMA
Mar-16
ABBOTT INDIA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs6,0151,720 349.7%   
Low Rs3,7071,103 336.1%   
Sales per share (Unadj.) Rs1,236.9194.6 635.6%  
Earnings per share (Unadj.) Rs122.245.2 270.2%  
Cash flow per share (Unadj.) Rs129.050.3 256.4%  
Dividends per share (Unadj.) Rs35.008.00 437.5%  
Dividend yield (eoy) %0.70.6 127.0%  
Book value per share (Unadj.) Rs521.2132.0 394.8%  
Shares outstanding (eoy) m21.2588.77 23.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.97.3 54.2%   
Avg P/E ratio x39.831.2 127.5%  
P/CF ratio (eoy) x37.728.1 134.3%  
Price / Book Value ratio x9.310.7 87.2%  
Dividend payout %28.617.7 161.9%   
Avg Mkt Cap Rs m103,296125,299 82.4%   
No. of employees `0003.0NA-   
Total wages/salary Rs m3,3702,570 131.1%   
Avg. sales/employee Rs Th8,891.8NM-  
Avg. wages/employee Rs Th1,140.0NM-  
Avg. net profit/employee Rs Th878.3NM-  
INCOME DATA
Net Sales Rs m26,28417,275 152.1%  
Other income Rs m504166 303.3%   
Total revenues Rs m26,78917,442 153.6%   
Gross profit Rs m3,6655,807 63.1%  
Depreciation Rs m144451 32.0%   
Interest Rs m849 16.6%   
Profit before tax Rs m4,0175,474 73.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4211,460 97.3%   
Profit after tax Rs m2,5964,014 64.7%  
Gross profit margin %13.933.6 41.5%  
Effective tax rate %35.426.7 132.6%   
Net profit margin %9.923.2 42.5%  
BALANCE SHEET DATA
Current assets Rs m14,4467,639 189.1%   
Current liabilities Rs m4,7252,715 174.0%   
Net working cap to sales %37.028.5 129.8%  
Current ratio x3.12.8 108.7%  
Inventory Days Days5143 118.9%  
Debtors Days Days2079 24.9%  
Net fixed assets Rs m1,1136,914 16.1%   
Share capital Rs m213177 120.1%   
"Free" reserves Rs m10,80811,442 94.5%   
Net worth Rs m11,07611,721 94.5%   
Long term debt Rs m0149 0.0%   
Total assets Rs m16,24114,814 109.6%  
Interest coverage x497.0112.9 440.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.61.2 138.8%   
Return on assets %16.027.4 58.5%  
Return on equity %23.434.2 68.4%  
Return on capital %36.346.5 78.1%  
Exports to sales %0.655.1 1.1%   
Imports to sales %12.66.0 210.5%   
Exports (fob) Rs m1629,527 1.7%   
Imports (cif) Rs m3,3221,038 320.2%   
Fx inflow Rs m26810,422 2.6%   
Fx outflow Rs m3,9271,678 234.0%   
Net fx Rs m-3,6598,744 -41.9%   
CASH FLOW
From Operations Rs m2,5143,264 77.0%  
From Investments Rs m-800-2,093 38.2%  
From Financial Activity Rs m-803-1,186 67.7%  
Net Cashflow Rs m912-15 -6,161.5%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 1.6 509.7%  
FIIs % 0.1 7.6 1.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 17.0 100.6%  
Shareholders   18,270 20,968 87.1%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 22, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS